Thr769
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr769  -  VCIP135 (mouse)

Site Information
tKAPysPttsKEKKI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 483405

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
brain cancer ( 1 ) , neuroendocrine cancer ( 1 )
Relevant cell line - cell type - tissue:
brain ( 1 ) , C2C12 (myoblast) ( 2 )

Upstream Regulation
Treatments:
BMP2 ( 2 )

References 

1

Guo A (2011) CST Curation Set: 12736; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

2

Kim BG, et al. (2009) 'Two-stage double-technique hybrid (TSDTH)' identification strategy for the analysis of BMP2-induced transdifferentiation of premyoblast C2C12 cells to osteoblast. J Proteome Res 8, 4441-54
19655815   Curated Info